ALK and non-small cell lung carcinoma: In this clinical trial, 154 previously treatment-naive patients with advanced NSCLC received pembrolizumab treatment and at least 50% of tumors cells of these patients expressed PD-L1 without EGFR or ALK genomic aberrations.